News

Researcher Spotlight: David Scott, MBCHB, PhD

The disease course for follicular lymphoma (FL) is highly variable, and while many patients respond to treatment, some may experience relapse or evolution of disease into a more aggressive form of lymphoma. By studying genetic mutations, gene and protein expression, and interactions between lymphoma cells and their environment, Dr. Scott’s LRF research aims to develop tools that can reliably predict patient outcomes and guide treatment decision-making.

The BCCF Innovation Support Fund Awardees are:

• Ly Vu & Christian Steidl - equipment: Bio-Rad ChemiDoc Imaging System
• Pamela Hoodless - equipment: Thermo EVOS M5000 Cell Imaging Microscope

The BC Cancer Foundation, in partnership with BC Cancer, established the Innovation Support Fund competition in 2010 to enable the acquisition of equipment essential to conducting research. 

It’s their fifth cycle of funding for researchers at the BC Cancer Centre for Lymphoid Cancer who are part of the renewal of a coveted Terry Fox New Frontiers Program Projects Grant, following the 2022 competition. 

Five Canadian cancer research teams will share $22.4 million to expand their research into key areas of cancer treatment after winning the 2022 Terry Fox New Frontiers Program Project Grant (PPG) competition. Notably, three of the program project leaders are women and funding from two partner organizations is supporting two projects.

Read the full press release here.

The Lymphoma Research Foundation (LRF) is the largest non-profit lymphoma research organization in North America with a volunteer scientific advisory board comprised of world-renowned lymphoma experts, including Dr. David Scott. Dr. Scott is the clinical director of the BC Cancer Centre for Lymphoid Cancer, deputy head of the BC Cancer Lymphoid Cancer Research and an associate professor at the University of British Columbia. Dr.